TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions

Anticancer Research

Volumn 19, Issue 1 B, 1999, Pages 849-851

  Cerwenka, Herwig ^a,b   Aigner, R ^a   Bacher, H ^a   Werkgartner, G ^a   El Shabrawi, A ^a   Quehenberger, F ^a   Mischinger, H J ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

CA19 9; CEA; Metastasis; Pancreatic cancer; Pyruvate kinase; TUM2 PK

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PYRUVATE KINASE; TUMOR MARKER;

ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HUMANS; NEOPLASM METASTASIS; PANCREATIC DISEASES; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0032923122     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Eigenhrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R: Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Critical Rev Oncogenesis 3: 91-115, 1992.
2. Eigenbrodt E, Fister P, Reinacher M: New perspectives of oncocarbohydrate metabolism in tumor cells. In: Regulation of Carbohydrate Metabolism, Vol.II, Breitner R(ed), CRC Press, Boca Raton, FL: 141-179, 1985.
3. Staal GEJ, Kalff A, Heesbeen EC, Van Veelen CWM, Rijksen G: Subunit composition, regulatory properties and posphorylation of phosphofructokinase from human gliomas. Cancer Res 47: 5047-5051, 1987.
4. Arora KK. Faniciulli M, Pedersoen PL: Glucose phosphorylation in tumor cells. Cloning, sequencing and overexpression in active form of full-length cDNA encoding a mitochondrial bindable form of hexokinase. J Biol Chem 265: 6481-6488, 1990.
5. Schwartz MK: Enzymes used in predicting high risk to colon cancer. Clin. Biochem 23: 395-398, 1990.
6. Scheefers-Borchel U, Scheefers H, Michel A, Will H, Fischer G, Basenau D, Dahlmann N, Laumen R, Mazurek S, Eigenbrodt E: Quantitative determination of pyruvate kinase type tumor M2. In: Current Diagnosis, Klapdor R (ed), W.Zuckerschwerdt Verlag, München, 1994
7. OremekGM, Eibenbrodt E, Raedle J, Zeuzem St, Sciffert UB: Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res 17: 3031-3034, 1997.
8. Mazurek S, Scheefers-Borchel U, Scheefers H, Michel A, Basenau D, Fischer G, Dahlmann N, Laumen R, Eigenbrodt E: Die Bedeutung der Pyruvatkinase in der Onkologie. Notabene medici 3: 97-103, 1993.
9. Cerwenka H, Aigner R, Quehenberger F, Werkgartner G. Bacher H, Hauser H, Mischinger HJ: Preoperative differential diagnosis of benign and malignant pancreatic lesions - the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA. Hepato-Gastroenterol 44: 1117-1121, 1997.
10. Beckner ME, Stracke ML, Liotta LA, Schiffmann E: Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst 82: 1836-1840, 1990.
11. Board M, Humm S, Newsholme EA: Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 265: 503-509, 1990.